Profile data is unavailable for this security.
About the company
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
- Revenue in USD (TTM)1.12m
- Net income in USD-16.76m
- Incorporated2010
- Employees93.00
- LocationX4 Pharmaceuticals Inc61 NORTH BEACON STREET, 4TH FLOORBOSTON 02134United StatesUSA
- Phone+1 (857) 529-8300
- Fax+1 (302) 655-5049
- Websitehttps://www.x4pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boundless Bio Inc | 0.00 | -61.06m | 57.31m | 72.00 | -- | 0.3465 | -- | -- | -2.75 | -2.75 | 0.00 | 7.42 | 0.00 | -- | -- | 0.00 | -38.30 | -- | -40.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -153.78m | 57.42m | 109.00 | -- | 0.3297 | -- | -- | -9.14 | -9.14 | 0.00 | 10.22 | 0.00 | -- | -- | 0.00 | -131.73 | -- | -168.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.24m | 57.87m | 31.00 | -- | 1.22 | -- | -- | -1.33 | -1.33 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -54.12 | -58.43 | -57.23 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Champions Oncology Inc | 51.66m | -3.40m | 58.05m | 210.00 | -- | -- | -- | 1.12 | -0.2541 | -0.2541 | 3.78 | -0.0244 | 1.88 | -- | 5.75 | 245,976.20 | -12.39 | -10.00 | -44.43 | -23.00 | 44.27 | 46.58 | -6.58 | -6.04 | -- | -- | 333.00 | -- | -6.90 | 13.13 | -36.38 | -- | 0.0479 | -- |
| Atara Biotherapeutics Inc | 100.44m | -133.16m | 60.09m | 159.00 | -- | -- | -- | 0.5982 | -26.44 | -26.44 | 18.00 | -15.77 | 0.606 | 1.69 | 134.10 | 446,395.60 | -80.34 | -70.20 | -276.19 | -86.94 | 82.70 | -- | -132.58 | -1,559.33 | 0.4993 | -46.83 | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Bioqual Inc | -100.00bn | -100.00bn | 60.37m | 108.00 | -- | 1.63 | -- | -- | -- | -- | -- | 41.34 | -- | -- | -- | -- | -- | 8.14 | -- | 9.52 | -- | 19.36 | -- | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Cue Biopharma Inc | 9.53m | -44.61m | 62.01m | 53.00 | -- | 2.44 | -- | 6.51 | -0.906 | -0.906 | 0.1925 | 0.4213 | 0.1677 | -- | 3.96 | 179,849.10 | -78.47 | -57.45 | -111.95 | -68.41 | -- | -- | -468.02 | -810.87 | -- | -- | 0.1726 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| X4 Pharmaceuticals Inc | 1.12m | -16.76m | 62.08m | 93.00 | -- | 1.04 | -- | 55.28 | -0.0853 | -0.0853 | 0.0056 | 0.3538 | 0.0064 | -- | 1.53 | 12,075.27 | -9.54 | -61.53 | -11.29 | -69.20 | 55.92 | -- | -1,492.34 | -13,288.93 | 4.80 | -- | 0.5579 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Immuneering Corp | 0.00 | -58.07m | 62.57m | 66.00 | -- | 1.14 | -- | -- | -1.97 | -1.97 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -63.66 | -- | -68.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Celularity Inc | 42.69m | -112.83m | 62.66m | 120.00 | -- | 2.25 | -- | 1.47 | -5.77 | -5.77 | 2.14 | 1.27 | 0.2236 | 3.92 | 4.65 | 355,750.00 | -59.09 | -19.19 | -90.61 | -20.99 | 60.24 | -- | -264.30 | -454.79 | 0.2182 | -11.18 | 0.5958 | -- | 26.68 | -- | -1,483.14 | -- | -- | -- |
| RetinalGenix Technologies Inc | 0.00 | -4.04m | 62.99m | 0.00 | -- | -- | -- | -- | -0.2291 | -0.2291 | 0.00 | -0.101 | 0.00 | -- | -- | -- | -9,059.05 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -1,050.46 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Spero Therapeutics Inc | 106.46m | 3.51m | 64.32m | 46.00 | 19.54 | 0.9867 | 17.94 | 0.6042 | 0.0609 | 0.0609 | 1.97 | 1.21 | 0.8788 | -- | 3.78 | 2,314,239.00 | 2.90 | -35.52 | 4.19 | -41.75 | -- | -- | 3.30 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Allovir Inc | 0.00 | -100.20m | 65.86m | 112.00 | -- | 0.5433 | -- | -- | -0.8755 | -0.8755 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -54.04 | -52.85 | -59.58 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Agenus Inc | 160.43m | -227.86m | 67.09m | 389.00 | -- | -- | -- | 0.4182 | -11.06 | -11.06 | 7.81 | -13.48 | 0.559 | -- | 259.38 | 412,408.80 | -81.56 | -55.02 | -663.00 | -115.31 | 99.61 | -- | -145.89 | -102.92 | -- | -0.7247 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Bioatla Inc | 11.00m | -81.82m | 67.20m | 65.00 | -- | 2.93 | -- | 6.11 | -1.70 | -1.70 | 0.2284 | 0.4751 | 0.103 | -- | -- | 169,230.80 | -76.61 | -48.72 | -103.22 | -57.35 | -- | -- | -743.79 | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Data as of Nov 22 2024. Currency figures normalised to X4 Pharmaceuticals Inc's reporting currency: US Dollar USD
26.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 10.35m | 6.14% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 8.13m | 4.83% |
| Kingdon Capital Management LLCas of 30 Sep 2024 | 4.64m | 2.75% |
| Adage Capital Management LPas of 30 Sep 2024 | 4.28m | 2.54% |
| Perceptive Advisors LLCas of 30 Sep 2024 | 3.55m | 2.10% |
| Geode Capital Management LLCas of 30 Sep 2024 | 3.45m | 2.05% |
| AXA Investment Managers UK Ltd.as of 30 Sep 2024 | 3.08m | 1.83% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.95m | 1.75% |
| Ensign Peak Advisors, Inc.as of 30 Sep 2024 | 2.55m | 1.51% |
| Schonfeld Strategic Advisors LLCas of 30 Sep 2024 | 1.92m | 1.14% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
